Lemborexant is a Small Molecule owned by Eisai, and is involved in 35 clinical trials, of which 26 were completed, 7 are ongoing, and 2 are planned.
Lemborexant (E-2006) is a dual orexin receptor antagonist (DORA). It induces sleep by non-selectively antagonizing the OX1 and OX2 receptors. Orexin maintains a long, consolidated waking period by activating waking monoaminergic and cholinergic neurons in the hypothalamus and brainstem regions. The inhibition of orexin receptor leads to inhibition of complication associated with insomnia.
The revenue for Lemborexant is expected to reach a total of $7.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lemborexant NPV Report.
Lemborexant is originated and owned by Eisai.
Lemborexant (E-2006/Dayvigo) is n-arylamide/carboxamide derivative acts as sedative/hypnotic agents. It is formulated as film coated tablets for oral route of administration. It is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.It is also indicated for the treatment of adult patients with insomnia.
Lemborexant (E-2006/Dayvigo) is under development for the treatment of gastroesophageal reflux disease, obstructive sleep apnea, chronic obstructive pulmonary disease, irregular sleep wake rhythm disorder and dementia associated with Alzheimer’s disease. It was also under development for chronic insomnia.
Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY756,226 million for the fiscal year ended March 2022 (FY2022), an increase of 17.1% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 8% in FY2021. In FY2022, the company recorded a net margin of 6.3%, compared to a net margin of 6.5% in FY2021. The company reported revenues of JPY174,364 million for the second quarter ended September 2022, a decrease of 5.4% over the previous quarter.
Quick View – Lemborexant
|Highest Development Stage|